Pharmacy Practice Sponsored Research
ADHERE Longitudinal Module-Registry of Severe Heart Failure Patients at High Risk for ReHospitalization
Scios Inc.
8/30/04 – 12/31/07
Vicki Groo, PharmD (PI)
The ADHERE REgistry LM is a multicenter, observational registry database of the management of advanced CHF patients treated in a minimum of 75 hospitals or outpatient clinics. The target population consists of patients with advanced CHF (NYHA class III or IV) at high risk for rehospitalization. Approximately 2,250 patients will be enrolled and will be followed for up to two years. Data will be collected via both clinical chart review and patient questionnaire. The objectives are: (1) to assess change in patient quality of life as a function of medical management and disease progression (2) describe practices of continuous, intermittent and periodic treatment of symptoms with outpatient IV vasoactive infusion (3) understand timing and course of HF disease progression; measure hospital readmissions and outcomes (4) assist with the optimization of HF management by providing information on the use of therapies proven to be effective.
Characterizing Gemcitabine-Paclitaxel Interaction
American Cancer Society
11/1/05 – 10/31/07
Stacy Shord, PharmD (PI)
Gemcitabine and paclitaxel are commonly administered together to patients with advanced breast, lung, and ovarian cancer. However, this combination only provides marginal benefit compared to either agent alone. This study aims to determine if paclitaxel limits the effectiveness of gemcitabine and to assess the effects of paclitaxel on the metabolism and transport of gemcitabine. This study will also aim to identify other drugs that may alter the effectiveness of gemcitabine or other similar chemotherapy agents.
Medication Therapy Management Program Design and Evaluation (Task Order No. 2 -UIC DEcIDE Research Network)
Agency for Healthcare Research and Quality - Center for Outcomes and Evidence
9/30/05 – 5/31/07
Daniel Touchette, PharmD (PI), Glen T. Schumock, PharmD, MBA, FCCP (Co-I), Mary Ann Kliethermes, PharmD (Co-I)
This task order aims to: 1) develop an MTM pilot program designed to reduce medication adverse effects and to develop a strategy to identify types of MTM programs offered nationally by Prescription Drug Plans (PDP); 2) evaluate the impact of two MTM programs of differing intensity on clinical outcomes, and; 3) determine which patient factors have the greatest impact on determining the success of one MTM program over another.
Phase I Clinical Studies of Chemopreventive Agents
National Cancer Institute
10/1/98 – 3/30/08
Keith A. Rodvold, PharmD (PI)
NOVO NORDISK and UIC Fellowship in Health Economics and Outcomes Research*
Novo Nordisk Inc.
7/1/07 – 6/30/08
Alan Simon Pickard, PhD
TAP-UIC Fellowship in Health Economics and Outcomes Research*
TAP Pharmaceutical Products Inc.
7/1/07 – 6/30/09
Alan Simon Pickard, PhD (PI), Glen T. Schumock, PharmD, MBA, FCCP (Co-I)
WHI-UIC Research Fellowship in Pharmaceutical Outcomes*
Walgreens Health Initiatives
9/16/07 – 9/15/08
Glen T. Schumock, PharmD, MBA, FCCP
*The overall aim these joint fellowship projects is to train independent clinical scientists with expertise and skills in health economics and outcomes research that can assume leadership positions in the pharmaceutical industry or academia.
Estimation of a Utility-Based Algorithm for EORTC QLQ-C3Q
Pfizer, Inc.
4/1/07 – 3/31/08
Alan Simon Pickard, PhD (PI), James Shaw, PhD, PharmD, MPH (Co-I)
The overall purpose of this study is to develop a set of preference-based weights that convert European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ) responses to a single utility score.
Anidulafungin Pharmacokinetics in Patients with Septic Shock and Hypoalbuminemia
Pfizer, Inc.
12/1/06 – 11/30/07
Eljim Tesoro, PharmD (PI), Nina Clark, MD (Co-I), Shellee Grim, PharmD, BCPS (Co-I)
This study will provide information on the pharmacokinetics of anidulafungin in critically ill patients with septic shock and hypoalbuminemia. Such information will be valuable in helping determine the optimal dose for this population.
Make Medicare Work Coalition
AgeOptions
6/1/07 – 12/31/07
JoAnn Stubbings. MHCA (PI), Sandra Durley, PharmD, RPh, (Co-I)
The purpose of this project is to identify people who are potentially eligible for Low Income Subsidy (LIS) and Medicare Part D and assist them with the LIS and Medicare Part D sign up process. UIC Pharmacy has been asked to sign up 100 people during 2007.
Efficacy of phosphate binding in hemodialysis patients: chewed vs. crushed lanthanum carbonate
Shire US, Inc.
9/1/06 – 8/31/08
Alan Lau, PharmD (PI), Jose Arruda, MD (Co-I)
The objective of this study is to compare the efficacy of phosphate binding between chewed and crushed lanthanum carbonate in patients undergoing hemodialysis.
Efficacy of phosphate binding in healthy volunteers: chewed vs. crushed lanthanum carbonate
Shire Development Inc.
9/1/06 – 8/31/08
Alan Lau, PharmD (PI)
The objective of this study is to compare the efficacy of phosphate binding between chewed and crushed lanthanum carbonate.
A 5-Yr Analysis of Antimicrobial Susceptibility Trends in the Chicagoland areas between 2005-2006
Astra Zeneca
6/1/07 – 12/01/08
Larry Danziger, PharmD (PI), Jomy Joseph, PharmD (Co-I)
The primary objective of this surveillance study is to update, identify, and relate susceptibility patterns in the Chicagoland area according to hospital demographics (ie. bed-size, teaching vs. non-teaching) based on the collection of hospital antibiograms from 2000-2005. The results of this research will provide healthcare practitioners an update on the local resistance patterns according to hospital demographics and Chicagoland location. Knowledge of these susceptibility patterns can be applied to all area hospitals and help to guide empiric antibiotic therapy.
A Multi-National, Multi-Center, Double-Blind, Randomized Parallel Group Study to Compare the Safety and Efficacy of 200mg PAR-101 taken q12h with 125mg Vancomycin taken q6h for Ten Days in Subjects with Clostridium Difficile-Associated Diarrhea
Optimer and PAR Pharmaceuticals, Inc.
3/1/07 – 12/31/07
Larry Danziger, PharmD (PI), Fred Zar, MD (Co-I), Sarah Langridge, PharmD (Co-I), Patricia Fischer, RN, CCRP (Co-I), Vanessa Sarda (Co-I), Ashwin Ravichandran (Co-I).
The primary objective of this pivotal study is to investigate the safety and efficacy of PAR-101 versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD). The cure rates at end of therapy (primary outcome) and recurrence rates (secondary outcome) will be evaluated and compared.
Sub-Award Modification No.7 Under PHS Grant No. U10 CA31946
TAP Pharmaceutical Products Inc.
4/1/07 – 3/31/08
Linda Bressler, PharmD, BCOP (PI)
University of Chicago
Under this subcontract with University of Chicago, the PI provides part-time support for the CALGB as the Director of Regulatory Affairs. The PI manages the regulatory activities of CALGB in related to drug acquisition, distribution and use, and oversees compliance with federal regulations in these areas. She is the primary CALGB liaison to the pharmaceutical industry regarding drug provision, drug distribution and related regulatory affairs.
Effects of female hormones on hepatic drug metabolism: clinical implication during pregnancy
American College of Clinical Pharmacy
9/1/07 – 8/31/08
Hyunyoung Jeong, PharmD, PhD (PI), James Fischer (Co-I)
The primary goal in this research project is to establish a firm link between the female hormones and altered hepatic elimination of drugs iin vitro systems, and to predict altered pharmokinetics of drugs during pregnancy using human hepatocytes.
A Comparison of the Impact of Eleven Types of Cancer on Quality of Life
Evanston Northwestern Healthcare
1/1/07 – 12/31/07
Alan Simon Pickard, PhD (PI)
The aim of the study is to compare the differential impact of types of cancer on patients in clinical trials in terms of domains of HRQL as represented by the FACT-G and EQ-5D.
Quality of Life According to the EQ-5D in Asthma and COPD
EuroQol Business Group
1/1/07 – 1/1/08
Alan Simon Pickard, PhD (PI), Caitlyn Wilke, Hsiang-Wen Lin
The objectives of the study are: (1) To gather informationon the utilities associated with asthma and COPS, and treatments of these conditions, in terms of HRQL as defined by the EQ-5D self classifier and summary scores, and (2) To summarize the evidence of validity and reliability of the EQ-5D when evaluated in studies of asthma and COPD patients.
A Comparative Effectiveness of Tiotropium in Patients with Chronic Obstructive Pulmonary Disease (COPD)
Agency for Healthcare Quality Research
8/1/07 –12/31/07
Alan Simon Pickard, PhD (PI), Glen T. Schumock, PharmD, MBA, FCCP (Co-I)
The overall goal of this project is to evaluate the comparative effectiveness of tiotropium to other COPD medications when used to modify an existing treatment regimen. This is vital to providers of a Part D benefit as triotropium likely has a major impact with respect to their respiratory benefit costs and a better understanding of its comparative effectiveness may help guide positioning on their formularies.
Effect of moderate liver impairment on the pharmacokinetics of saquinavir after administration of saquinavir/ritonavir 1000/100 mg bid in HIV patients
Hoffman La-Roche, Inc.
3/1/06 – 9/15/08
Keith A. Rodvold, PharmD (PI), Maximo Brito, (Co-I)
The primary objective of the study is to assess the effect of moderate liver impairment on the plasma drug concentrations of saquinavir in patients with HIV infection. The secondary objectives of the study are: 1) to assess the effect of moderate liver impairment on the plasma drug concentrations of ritonavir in patients with HIV infection; 2) To evaluate the plasma drug concentrations of saquinavir and ritonavir in patients with HIV infection and who are co-infected with hepatitis B and/or C and raised liver enzymes, and: 3) To investigate the safety and tolerability of saquinavir combined with ritonavir in patients with HIV infection and moderate liver impairment.
Virtual Eye and Virtual House
Allergan, Inc.
6/1/07 – 5/31/08
Richard Fiscella, RPh, MPH (PI)
UIC's stereoscopic Virtual Eye and Virtual House provide detailed insights into diseases two-dimensional pictures cannot. The VE application uses stereovision and interaction to give viewers a unique opportunity to better understand the complex, three-dimensional structure of the eye. The VH creates a virtual 3-D tour through the hallways and rooms of a furnished home, as experienced by someone with normal vision and with visual impairment. The projections for the left eye and the right eye are computed separately, allowing simulation of problems in stereovision and different visual defects in each eye. The model would appeal to audiences such as patients, health care practitioners, eye care professionals, and eye care specialists.
Risperidone-Induced Prolactin Elevation and Bone Turnover in Adolescents
American College of Clinical Pharmacy
7/1/06 –6/30/07
Jeffrey R. Bishop, PharmD (PI), Mani Pavuluri (Co-I)
The primary objectives of this study are to characterize the relationship between risperidone-induced PRL elevation and bone turnover in youth with bipolar disorder, to determine the relationship between DRD2 pharmacogenetics (known to regulate PRL release in the pituitary) and variability in PRL elevation, and finally to assess collective effects of functional polymorphisms that affecting DA disposition on the PRL elevation. The rationale for this study is that the long-term consequences of treating children with an agent that may increase bone turnover are not known and we need to determine if there is the potential for long-term risk and develop appropriate interventions if necessary.